Gary Ulaner

Title(s)Clinical Professor of Radiology and Translational Genomics (Part Time)
SchoolKeck School of Medicine of Usc
Address19582 Beach Blvd
Off Campus
Huntington Beach CA 92648
Phone+1 949 557 0285
ORCID ORCID Icon0000-0002-7953-0113 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Rutgers University, New Brunswick, NJBA05/1993Biology
    Stanford University School of Medicine, Stanford, CAMD, PhD06/2000Cancer Biology
    Johns Hopkins , Baltimore, MD06/2001Internship
    University of Southern California, Los Angeles, CA06/2009Diagnostic Radiology
    University of Southern California, Los Angeles, CA06/2009Nuclear Medicine
    Collapse Awards and Honors
    1994National Institutes of Health Cancer Biology Pre-Doctoral Fellowship
    1997National Institutes of Health Medical Scientist Training Program
    2001National Institutes of Health Post-Doctoral Fellowship
    2005RSNA Roentgen Resident Research Award
    2009Resident of the Year, University of Southern California
    2011RSNA Excellence Award for Research
    2012Susan Komen for the Cure Career Catalyst Award
    2014Department of Defense Breakthrough Award
    2015Radiographics Educational Design Award
    2015Radiology Editor’s Recognition Award with Special Distinction
    2016Radiology Editor’s Recognition Award with Special Distinction
    2016Jon Shevell Young Scientist Scholarship, Susan Komen Foundation
    2016SNMMI Best Breast Cancer Research Abstract
    2016SNMMI first place prize in Basic Science
    2016MSKCC Department of Radiology, Excellence in Teaching Award
    2016Weill Cornell Department of Radiology, Best Teacher
    2017Jon Shevell Award from the Susan Komen Foundation
    2017Clinical Nuclear Medicine Editor’s Award
    2017Elected Fellow, American College of Nuclear Medicine
    2018First Hal O’Brien Rising Star Award, Society of Nuclear Medicine and Molecular Imaging (SNMMI)
    2019American College of Nuclear Medicine – President’s Award
    2021James and Pamela Muzzy Endowed Chair

    Collapse Overview 
    Collapse Overview
    Dr. Gary Ulaner is the James & Pamela Muzzy Endowed Chair of Molecular Imaging and Therapy (MIT) at the Hoag Family Cancer Institute and Professor of Radiology and Translational Genomics at the University of Southern California.

    Gary has been the principal investigator of prospective clinical trials for six novel PET radiotracers for patients with breast cancer, prostate cancer and myeloma, funded by two National Institutes of Health R01s, as well as grants from the Department of Defense (DoD) Breast Cancer Research Programs, Susan G. Komen Foundation, and Rising Tide Foundation. His clinical trials emphasize targeted imaging to guide targeted therapy of cancer, particularly ER, HER2, PSMA and CD38 targeted PET imaging.

    Gary in on the editorial board of 4 leading radiology journals, authored the text “Fundamentals of Oncologic PET/CT”, and is on the scientific advisory boards of ImaginAb, GE Healthcare, and the Lobular Breast Cancer Alliance.

    Gary currently lives in Irvine, California, with his wife, Alena, son, Ilya, and daughter, Anabel. He met his wife swing dancing, and they are still dancing today, albeit with less frequency.

    Collapse Research 
    Collapse Research Activities and Funding
    Molecular Pathogenesis and Therapy of Systemic Histiocytic Neoplasms
    NIH R37CA259260Apr 1, 2021 - Mar 31, 2026
    Role: Co-Investigator
    Improved staging of lobular breast cancer with novel amino acid metabolic and tumor neovasculature receptor imaging.
    NIH R21CA256280Dec 9, 2020 - Nov 30, 2022
    Role: Co-Investigator
    CD38-targeted immunoPET of myeloma: Phase 2 trial of clinical applications
    NIH R01CA248398Jul 1, 2020 - Jan 31, 2024
    Role: Principal Investigator
    The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab
    NIH R01CA204167Apr 1, 2016 - Mar 31, 2021
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. High resolution and high sensitivity PET for quantitative molecular imaging of the monoaminergic nuclei: A GATE simulation study. Med Phys. 2022 Apr 07. Wang Z, Cao X, LaBella A, Zeng X, Biegon A, Franceschi D, Petersen E, Clayton N, Ulaner GA, Zhao W, Goldan AH. PMID: 35390182.
      View in: PubMed   Mentions:
    2. 16α-18F-fluoro-17β-Fluoroestradiol (FES): Clinical Applications for Patients With Breast Cancer. Semin Nucl Med. 2022 Apr 01. Ulaner GA. PMID: 35379454.
      View in: PubMed   Mentions:
    3. Value of MRI in evaluating urachal carcinoma: A single center retrospective study. Urol Oncol. 2022 Jul; 40(7):345.e9-345.e17. Das JP, Woo S, Ghafoor S, Andrieu PIC, Ulaner GA, Donahue TF, Goh AC, Vargas HA. PMID: 35351368.
      View in: PubMed   Mentions:
    4. Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. J Clin Oncol. 2022 Mar 20; 40(9):997-1008. Chi P, Qin LX, Nguyen B, Kelly CM, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Thornton KA, Crago AM, Yoon S, Ulaner G, Yeh R, Martindale M, Phelan HT, Biniakewitz MD, Warda S, Lee CJ, Berger MF, Schultz ND, Singer S, Hwang S, Chen Y, Antonescu CR, Tap WD. PMID: 35041493; PMCID: PMC8937014.
      View in: PubMed   Mentions:
    5. Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clin Cancer Res. 2021 10 01; 27(19):5195-5212. Anderson KC, Auclair D, Adam SJ, Agarwal A, Anderson M, Avet-Loiseau H, Bustoros M, Chapman J, Connors DE, Dash A, Di Bacco A, Du L, Facon T, Flores-Montero J, Gay F, Ghobrial IM, Gormley NJ, Gupta I, Higley H, Hillengass J, Kanapuru B, Kazandjian D, Kelloff GJ, Kirsch IR, Kremer B, Landgren O, Lightbody E, Lomas OC, Lonial S, Mateos MV, Montes de Oca R, Mukundan L, Munshi NC, O'Donnell EK, Orfao A, Paiva B, Patel R, Pugh TJ, Ramasamy K, Ray J, Roshal M, Ross JA, Sigman CC, Thoren KL, Trudel S, Ulaner G, Valente N, Weiss BM, Zamagni E, Kumar SK. PMID: 34321279.
      View in: PubMed   Mentions: 1     Fields:    
    6. CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody. J Nucl Med. 2022 05; 63(5):720-726. Farwell MD, Gamache RF, Babazada H, Hellmann MD, Harding JJ, Korn R, Mascioni A, Le W, Wilson I, Gordon MS, Wu AM, Ulaner GA, Wolchok JD, Postow MA, Pandit-Taskar N. PMID: 34413145; PMCID: PMC9051598.
      View in: PubMed   Mentions:
    7. Letter to the Editor: PET/CT in Locally Advanced Breast Cancer: Time for a Guideline Change? J Natl Compr Canc Netw. 2021 08 01; 19(8):xxx. Groheux D, Hindié E, Espié M, Ulaner GA. PMID: 34416711.
      View in: PubMed   Mentions:
    8. Evidence-Based Best Practices: 18F-FDG PET Staging of Newly Diagnosed Breast Cancer. Clin Nucl Med. 2021 07 01; 46(7):569-570. Ulaner GA, Jacene HA, Parihar AS, Groheux D. PMID: 34028402.
      View in: PubMed   Mentions:
    9. Intra-arterial Melphalan for Neurologic Non-Langerhans Cell Histiocytosis. Neurology. 2021 06 08; 96(23):1091-1093. Francis JH, Gobin YP, Alshiekh Nasany R, Knopman J, Ulaner GA, Panageas KS, Hatzoglou V, Salvaggio K, Abramson DH, Patsalides A, Diamond EL. PMID: 33980709; PMCID: PMC8205455.
      View in: PubMed   Mentions:
    10. 18F-FDG-Avid Lymph Nodes After COVID-19 Vaccination on 18F-FDG PET/CT. Clin Nucl Med. 2021 May 01; 46(5):433-434. Ulaner GA, Giuliano P. PMID: 33782318.
      View in: PubMed   Mentions:
    11. Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker. J Nucl Med. 2021 09 01; 62(9):1278-1284. Chan DL, Ulaner GA, Pattison D, Wyld D, Ladwa R, Kirchner J, Li BT, Lai WV, Pavlakis N, Roach PJ, Bailey DL. PMID: 33579809; PMCID: PMC8882901.
      View in: PubMed   Mentions:
    12. Author Correction: Accelerated single cell seeding in relapsed multiple myeloma. Nat Commun. 2021 Jan 20; 12(1):591. Landau HJ, Yellapantula V, Diamond BT, Rustad EH, Maclachlan KH, Gundem G, Medina-Martinez J, Ossa JA, Levine MF, Zhou Y, Kappagantula R, Baez P, Attiyeh M, Makohon-Moore A, Zhang L, Boyle EM, Ashby C, Blaney P, Patel M, Zhang Y, Dogan A, Chung DJ, Giralt S, Lahoud OB, Peled JU, Scordo M, Shah G, Hassoun H, Korde NS, Lesokhin AM, Lu S, Mailankody S, Shah U, Smith E, Hultcrantz ML, Ulaner GA, van Rhee F, Morgan GJ, Landgren O, Papaemmanuil E, Iacobuzio-Donahue C, Maura F. PMID: 33473129; PMCID: PMC7817844.
      View in: PubMed   Mentions:    Fields:    
    13. Improved image reconstruction of 89Zr-immunoPET studies using a Bayesian penalized likelihood reconstruction algorithm. EJNMMI Phys. 2021 Jan 19; 8(1):6. Kirchner J, O'Donoghue JA, Becker AS, Ulaner GA. PMID: 33469848; PMCID: PMC7815860.
      View in: PubMed   Mentions:
    14. Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue. Clin Lymphoma Myeloma Leuk. 2021 04; 21(4):230-237.e12. Kumar A, Bantilan KS, Jacob AP, Park A, Schoninger SF, Sauter C, Ulaner GA, Casulo C, Faham M, Kong KA, Grewal RK, Gerecitano J, Hamilton A, Hamlin P, Matasar M, Moskowitz CH, Noy A, Palomba ML, Portlock CS, Younes A, Willis T, Zelenetz AD. PMID: 33558202.
      View in: PubMed   Mentions:
    15. Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy. J Nucl Med. 2021 01; 62(1):6-14. Wahl RL, Chareonthaitawee P, Clarke B, Drzezga A, Lindenberg L, Rahmim A, Thackeray J, Ulaner GA, Weber W, Zukotynski K, Sunderland J. PMID: 33334911.
      View in: PubMed   Mentions:
    16. Diffusion and Perfusion MRI Predicts Response Preceding and Shortly After Radiosurgery to Brain Metastases: A Pilot Study. J Neuroimaging. 2021 03; 31(2):317-323. Shah AD, Shridhar Konar A, Paudyal R, Oh JH, LoCastro E, Nuñez DA, Swinburne N, Vachha B, Ulaner GA, Young RJ, Holodny AI, Beal K, Shukla-Dave A, Hatzoglou V. PMID: 33370467; PMCID: PMC8005428.
      View in: PubMed   Mentions:
    17. 18F-FDG PET/CT Helps Differentiate Peripheral Nerve Myeloid Sarcoma From a Presumed Benign Nerve Sheath Tumor. Clin Nucl Med. 2020 Dec; 45(12):989-991. Das JP, Riedl CC, Ulaner GA. PMID: 32956122.
      View in: PubMed   Mentions:
    18. The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim-Chester Disease. Cancers (Basel). 2020 Nov 03; 12(11). Weissman R, Diamond EL, Haroche J, Pillar N, Shapira G, Durham BH, Buthorn J, Cohen F, Ki M, Stemer G, Ulaner GA, Amoura Z, Emile JF, Mazor RD, Shomron N, Abdel-Wahab OI, Shpilberg O, Hershkovitz-Rokah O. PMID: 33153128; PMCID: PMC7693724.
      View in: PubMed   Mentions:
    19. Extramedullary Myeloma of the Uterus on 18F-FDG PET/CT: A Rare Manifestation of Multiple Myeloma. Clin Nucl Med. 2020 Nov; 45(11):873-875. Causa Andrieu PI, Das JP, Woo S, Ryan R, Akin O, Ulaner GA. PMID: 32657873.
      View in: PubMed   Mentions:
    20. Malignant perivascular epithelioid cell tumor of the ileum on 18F-fluorodeoxyglucose positron emission tomography/ computed tomography with pathological correlation. World J Nucl Med. 2021 Apr-Jun; 20(2):208-210. Das JP, Bou-Ayache J, Gollub MJ, Riedl CC, Ulaner GA. PMID: 34321979; PMCID: PMC8286011.
      View in: PubMed   Mentions:
    21. 18F-FDG PET/CT versus anatomic imaging for evaluating disease extent and clinical trial eligibility in Erdheim-Chester disease: results from 50 patients in a registry study. Eur J Nucl Med Mol Imaging. 2021 04; 48(4):1154-1165. Kirchner J, Hatzoglou V, Buthorn JB, Bossert D, Sigler AM, Reiner AS, Ulaner GA, Diamond EL. PMID: 33057928; PMCID: PMC8041681.
      View in: PubMed   Mentions:
    22. Acute Aortic Dissection Initially Suspected on 18F-FDG PET/CT. Clin Nucl Med. 2020 Oct; 45(10):819-820. Ulaner GA, Muehlbauer S, Goldberg Z. PMID: 32701812.
      View in: PubMed   Mentions:
    23. Clinical Utility of 18F-FDG PET/CT for Staging and Treatment Planning in Urachal Adenocarcinoma. J Nucl Med. 2021 05 10; 62(5):643-647. Das JP, Vargas HA, Ghafoor S, Goh AC, Ulaner GA. PMID: 32948680; PMCID: PMC8844264.
      View in: PubMed   Mentions:
    24. Mucinous urachal adenocarcinoma: A potential nonfluorodeoxyglucose-avid pitfall on 18fluorine-fluorodeoxyglucose positron emission tomography/computed tomography. World J Nucl Med. 2020 Oct-Dec; 19(4):432-434. Das JP, Vargas HA, Ulaner GA. PMID: 33623517; PMCID: PMC7875043.
      View in: PubMed   Mentions:
    25. Laboratory-Proven Asymptomatic SARS-CoV-2 (COVID-19) Infection on 18F-FDG PET/CT. Clin Nucl Med. 2020 Aug; 45(8):654-655. Krebs S, Petkovska I, Ho AL, Ulaner GA. PMID: 32433161; PMCID: PMC7268849.
      View in: PubMed   Mentions:
    26. Head-to-Head Evaluation of 18F-FES and 18F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer. J Nucl Med. 2021 03; 62(3):326-331. Ulaner GA, Jhaveri K, Chandarlapaty S, Hatzoglou V, Riedl CC, Lewis JS, Mauguen A. PMID: 32680923; PMCID: PMC8049349.
      View in: PubMed   Mentions:
    27. Accelerated single cell seeding in relapsed multiple myeloma. Nat Commun. 2020 07 17; 11(1):3617. Landau HJ, Yellapantula V, Diamond BT, Rustad EH, Maclachlan KH, Gundem G, Medina-Martinez J, Ossa JA, Levine MF, Zhou Y, Kappagantula R, Baez P, Attiyeh M, Makohon-Moore A, Zhang L, Boyle EM, Ashby C, Blaney P, Patel M, Zhang Y, Dogan A, Chung DJ, Giralt S, Lahoud OB, Peled JU, Scordo M, Shah G, Hassoun H, Korde NS, Lesokhin AM, Lu S, Mailankody S, Shah U, Smith E, Hultcrantz ML, Ulaner GA, van Rhee F, Morgan GJ, Landgren O, Papaemmanuil E, Iacobuzio-Donahue C, Maura F. PMID: 32680998; PMCID: PMC7368016.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    28. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity. Blood Rev. 2021 03; 46:100732. Diamond BT, Rustad E, Maclachlan K, Thoren K, Ho C, Roshal M, Ulaner GA, Landgren CO. PMID: 32771227.
      View in: PubMed   Mentions:
    29. Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. Neuro Oncol. 2020 07 07; 22(7):979-992. Bhatia A, Hatzoglou V, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Yabe M, Petrova-Drus K, Panageas KS, Reiner A, Rosenblum M, Diamond EL. PMID: 31950179; PMCID: PMC7339889.
      View in: PubMed   Mentions:
    30. Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT. Radiology. 2020 08; 296(2):370-378. Ulaner GA, Carrasquillo JA, Riedl CC, Yeh R, Hatzoglou V, Ross DS, Jhaveri K, Chandarlapaty S, Hyman DM, Zeglis BM, Lyashchenko SK, Lewis JS. PMID: 32515679; PMCID: PMC7543717.
      View in: PubMed   Mentions:
    31. Rosai-Dorfman Disease-Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-up. Clin Nucl Med. 2020 Jun; 45(6):e260-e266. Mahajan S, Nakajima R, Yabe M, Dogan A, Ulaner GA, Yahalom J, Noy A, Diamond EL, Schöder H. PMID: 32349088; PMCID: PMC8177955.
      View in: PubMed   Mentions:
    32. CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. Radiology. 2020 06; 295(3):606-615. Ulaner GA, Sobol NB, O'Donoghue JA, Kirov AS, Riedl CC, Min R, Smith E, Carter LM, Lyashchenko SK, Lewis JS, Landgren CO. PMID: 32255416; PMCID: PMC7263286.
      View in: PubMed   Mentions:
    33. HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers. Cancer Discov. 2020 05; 10(5):674-687. Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, Shifman S, Tu HY, Myers ML, Xu C, Mattar M, Khodos I, Little M, Qeriqi B, Weitsman G, Wilhem CJ, Lalani AS, Diala I, Freedman RA, Lin NU, Solit DB, Berger MF, Barber PR, Ng T, Offin M, Isbell JM, Jones DR, Yu HA, Thyparambil S, Liao WL, Bhalkikar A, Cecchi F, Hyman DM, Lewis JS, Buonocore DJ, Ho AL, Makker V, Reis-Filho JS, Razavi P, Arcila ME, Kris MG, Poirier JT, Shen R, Tsurutani J, Ulaner GA, de Stanchina E, Rosen N, Rudin CM, Scaltriti M. PMID: 32213539; PMCID: PMC7196485.
      View in: PubMed   Mentions:
    34. Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders. Best Pract Res Clin Haematol. 2020 03; 33(1):101148. Ulaner GA, Landgren CO. PMID: 32139013; PMCID: PMC7410322.
      View in: PubMed   Mentions:
    35. The QIBA Profile for FDG PET/CT: Improving the Value of PET. Radiology. 2020 Mar; 294(3):658-659. Ulaner GA. PMID: 31910074; PMCID: PMC7051153.
      View in: PubMed   Mentions:
    36. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and In vivo Performance of 89Zr-DFO-Pertuzumab. Theranostics. 2020; 10(4):1746-1757. Vivier D, Fung K, Rodriguez C, Adumeau P, Ulaner GA, Lewis JS, Sharma SK, Zeglis BM. PMID: 32042334; PMCID: PMC6993239.
      View in: PubMed   Mentions:
    37. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer Discov. 2020 02; 10(2):198-213. Smyth LM, Piha-Paul SA, Won HH, Schram AM, Saura C, Loi S, Lu J, Shapiro GI, Juric D, Mayer IA, Arteaga CL, de la Fuente MI, Brufksy AM, Spanggaard I, Mau-Sørensen M, Arnedos M, Moreno V, Boni V, Sohn J, Schwartzberg LS, Gonzàlez-Farré X, Cervantes A, Bidard FC, Gorelick AN, Lanman RB, Nagy RJ, Ulaner GA, Chandarlapaty S, Jhaveri K, Gavrila EI, Zimel C, Selcuklu SD, Melcer M, Samoila A, Cai Y, Scaltriti M, Mann G, Xu F, Eli LD, Dujka M, Lalani AS, Bryce R, Baselga J, Taylor BS, Solit DB, Meric-Bernstam F, Hyman DM. PMID: 31806627; PMCID: PMC7007377.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    38. Patient Repositioning Reveals a Malignant Pleura Effusion Initially Mistaken as a Bone Metastasis on 18FDG PET/CT. Clin Nucl Med. 2019 Dec; 44(12):969-970. Kirchner J, Riedl CC, Ulaner GA. PMID: 31689279.
      View in: PubMed   Mentions:
    39. Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med. 2019 12; 25(12):1839-1842. Durham BH, Lopez Rodrigo E, Picarsic J, Abramson D, Rotemberg V, De Munck S, Pannecoucke E, Lu SX, Pastore A, Yoshimi A, Mandelker D, Ceyhan-Birsoy O, Ulaner GA, Walsh M, Yabe M, Petrova-Drus K, Arcila ME, Ladanyi M, Solit DB, Berger MF, Hyman DM, Lacouture ME, Erickson C, Saganty R, Ki M, Dunkel IJ, Santa-María López V, Mora J, Haroche J, Emile JF, Decaux O, Geissmann F, Savvides SN, Drilon A, Diamond EL, Abdel-Wahab O. PMID: 31768065; PMCID: PMC6898787.
      View in: PubMed   Mentions:
    40. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial. JAMA Netw Open. 2019 11 01; 2(11):e1916211. Iyengar NM, Smyth LM, Lake D, Gucalp A, Singh JC, Traina TA, DeFusco P, Fornier MN, Goldfarb S, Jhaveri K, Modi S, Troso-Sandoval T, Patil S, Ulaner GA, Jochelson M, Norton L, Hudis CA, Dang CT. PMID: 31774522; PMCID: PMC6902832.
      View in: PubMed   Mentions:
    41. ACR Appropriateness Criteria® Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women. J Am Coll Radiol. 2019 Nov; 16(11S):S428-S439. Expert Panel on Breast Imaging, Lewin AA, Moy L, Baron P, Didwania AD, diFlorio-Alexander RM, Hayward JH, Le-Petross HT, Newell MS, Rewari A, Scheel JR, Stuckey AR, Suh WW, Ulaner GA, Vincoff NS, Weinstein SP, Slanetz PJ. PMID: 31685110.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    42. Focal Immunotherapy-Induced Pancreatitis Mimicking Metastasis on FDG PET/CT. Clin Nucl Med. 2019 Oct; 44(10):836-837. Das JP, Halpenny D, Do RK, Ulaner GA. PMID: 31283599.
      View in: PubMed   Mentions:
    43. Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. Clin Cancer Res. 2019 12 15; 25(24):7381-7387. Ulaner GA, Saura C, Piha-Paul SA, Mayer I, Quinn D, Jhaveri K, Stone B, Shahin S, Mann G, Dujka M, Bryce R, Meric-Bernstam F, Solit DB, Hyman DM. PMID: 31548342; PMCID: PMC7418635.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    44. PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact? AJR Am J Roentgenol. 2019 08; 213(2):254-265. Ulaner GA. PMID: 31063423.
      View in: PubMed   Mentions:
    45. Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT. Clin Nucl Med. 2019 Apr; 44(4):330-331. Ulaner GA, Bodei L. PMID: 30688738; PMCID: PMC6687392.
      View in: PubMed   Mentions:
    46. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 03; 567(7749):521-524. Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. PMID: 30867592; PMCID: PMC6438729.
      View in: PubMed   Mentions:
    47. Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clin Cancer Res. 2019 Feb 15; 25(4):1435. Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA. PMID: 30770494.
      View in: PubMed   Mentions:
    48. Detection of recurrent pancreatic cancer: value of second-opinion interpretations of cross-sectional images by subspecialized radiologists. Abdom Radiol (NY). 2019 02; 44(2):586-592. Huicochea Castellanos S, Corrias G, Ulaner GA, Dunphy M, Junting Z, Capanu M, Balachandran V, Giancipoli RG, Monti S, Mannelli L. PMID: 30251132; PMCID: PMC6399065.
      View in: PubMed   Mentions:
    49. Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2019 02; 566(7745):E11-E12. Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. PMID: 30755741.
      View in: PubMed   Mentions: 2     Fields:    
    50. ACR Appropriateness Criteria® Evaluation of the Symptomatic Male Breast. J Am Coll Radiol. 2018 Nov; 15(11S):S313-S320. Expert Panel on Breast Imaging:, Niell BL, Lourenco AP, Moy L, Baron P, Didwania AD, diFlorio-Alexander RM, Heller SL, Holbrook AI, Le-Petross HT, Lewin AA, Mehta TS, Slanetz PJ, Stuckey AR, Tuscano DS, Ulaner GA, Vincoff NS, Weinstein SP, Newell MS. PMID: 30392600.
      View in: PubMed   Mentions:
    51. 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Breast Cancer in Men. J Nucl Med. 2019 04; 60(4):472-477. Ulaner GA, Juarez J, Riedl CC, Goldman DA. PMID: 30237211; PMCID: PMC6448458.
      View in: PubMed   Mentions:
    52. Factors Affecting Oncologic Outcomes of 90Y Radioembolization of Heavily Pre-Treated Patients With Colon Cancer Liver Metastases. Clin Colorectal Cancer. 2019 03; 18(1):8-18. Kurilova I, Beets-Tan RGH, Flynn J, Gönen M, Ulaner G, Petre EN, Edward Boas F, Ziv E, Yarmohammadi H, Klompenhouwer EG, Cercek A, Kemeny NA, Sofocleous CT. PMID: 30297264; PMCID: PMC6884072.
      View in: PubMed   Mentions:
    53. Mazabraud's Syndrome Mimicking Metastases on FDG PET/CT in a Patient With Colon Cancer. Clin Nucl Med. 2018 Aug; 43(8):625-626. Mahajan S, Goel R, Riedl C, Ulaner GA. PMID: 29863575; PMCID: PMC6756475.
      View in: PubMed   Mentions:
    54. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. J Clin Oncol. 2018 08 20; 36(24):2532-2537. Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG. PMID: 29989854; PMCID: PMC6366814.
      View in: PubMed   Mentions:
    55. Diagnostic Role of Fluorodeoxyglucose PET in Breast Cancer: A History to Current Application. PET Clin. 2018 Jul; 13(3):355-361. Chakraborty D, Basu S, Ulaner GA, Alavi A, Kumar R. PMID: 30100075.
      View in: PubMed   Mentions:
    56. Amino Acid Metabolism as a Target for Breast Cancer Imaging. PET Clin. 2018 Jul; 13(3):437-444. Ulaner GA, Schuster DM. PMID: 30100081; PMCID: PMC6092023.
      View in: PubMed   Mentions:
    57. Uses and Opportunities for Molecular Imaging in Patients with Breast Cancer. PET Clin. 2018 07; 13(3):xi-xii. McDonald ES, Ulaner GA. PMID: 30100083.
      View in: PubMed   Mentions:
    58. Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer. PET Clin. 2018 Jul; 13(3):423-435. Henry KE, Ulaner GA, Lewis JS. PMID: 30100080; PMCID: PMC6092024.
      View in: PubMed   Mentions:
    59. 90Y Resin Microspheres Radioembolization for Colon Cancer Liver Metastases Using Full-Strength Contrast Material. Cardiovasc Intervent Radiol. 2018 Sep; 41(9):1419-1427. Kurilova I, Beets-Tan RGH, Ulaner GA, Boas FE, Petre EN, Yarmohammadi H, Ziv E, Deipolyi AR, Brody LA, Gonen M, Sofocleous CT. PMID: 29766239; PMCID: PMC6853060.
      View in: PubMed   Mentions:
    60. Molecular Classification of Breast Cancer. PET Clin. 2018 Jul; 13(3):325-338. Provenzano E, Ulaner GA, Chin SF. PMID: 30100073.
      View in: PubMed   Mentions:
    61. Adalimumab-Induced Epstein-Barr Virus-Related Lymphoproliferative Disorder on FDG PET/CT. Clin Nucl Med. 2018 May; 43(5):344-345. Ward J, Noy A, Ulaner G, Riedl C. PMID: 29538028.
      View in: PubMed   Mentions:
    62. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. JAMA Oncol. 2018 Mar 01; 4(3):384-388. Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, Martínez-Valle F, Durham B, Arcila ME, Ulaner G, Abdel-Wahab O, Pitcher B, Makrutzki M, Riehl T, Baselga J, Hyman DM. PMID: 29188284; PMCID: PMC5844839.
      View in: PubMed   Mentions:
    63. Single-agent dabrafenib for BRAFV600E-mutated histiocytosis. Haematologica. 2018 04; 103(4):e177-e180. Bhatia A, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Lacouture ME, Hajdenberg J, Ganzel C, Diamond EL. PMID: 29472347; PMCID: PMC5865413.
      View in: PubMed   Mentions:
    64. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 02 08; 554(7691):189-194. Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB. PMID: 29420467; PMCID: PMC5808581.
      View in: PubMed   Mentions: 162     Fields:    Translation:HumansCTClinical Trials
    65. Trends in oncologic hybrid imaging. Eur J Hybrid Imaging. 2018; 2(1):1. Wibmer AG, Hricak H, Ulaner GA, Weber W. PMID: 29782605; PMCID: PMC5954767.
      View in: PubMed   Mentions:
    66. Specialized second-opinion radiology review of PET/CT examinations for patients with diffuse large B-cell lymphoma impacts patient care and management. Medicine (Baltimore). 2017 Dec; 96(51):e9411. Sawan P, Rebeiz K, Schoder H, Batlevi C, Moskowitz A, Ulaner GA, Dunphy M, Mannelli L. PMID: 29390562; PMCID: PMC5758264.
      View in: PubMed   Mentions:
    67. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. Clin Nucl Med. 2017 Dec; 42(12):912-917. Ulaner GA, Hyman DM, Lyashchenko SK, Lewis JS, Carrasquillo JA. PMID: 28872549; PMCID: PMC5708879.
      View in: PubMed   Mentions:
    68. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer. J Nucl Med. 2018 06; 59(6):900-906. Ulaner GA, Lyashchenko SK, Riedl C, Ruan S, Zanzonico PB, Lake D, Jhaveri K, Zeglis B, Lewis JS, O'Donoghue JA. PMID: 29146695; PMCID: PMC6004559.
      View in: PubMed   Mentions:
    69. David Versus the Goliaths for the Detection of Bone Metastases. J Nucl Med. 2017 11; 58(11):1776-1777. Ulaner GA. PMID: 28818986.
      View in: PubMed   Mentions:
    70. Long-Half-Life 89Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer. J Nucl Med. 2018 03; 59(3):399-402. Cornelis FH, Durack JC, Pandit-Taskar N, Ulaner GA, Lewis JS, Morris MJ, Solomon SB. PMID: 28818992; PMCID: PMC5868497.
      View in: PubMed   Mentions:
    71. High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood. 2017 08 24; 130(8):1007-1013. Papo M, Diamond EL, Cohen-Aubart F, Emile JF, Roos-Weil D, Gupta N, Durham BH, Ozkaya N, Dogan A, Ulaner GA, Rampal R, Kahn JE, Sené T, Charlotte F, Hervier B, Besnard C, Bernard OA, Settegrana C, Droin N, Hélias-Rodzewicz Z, Amoura Z, Abdel-Wahab O, Haroche J. PMID: 28679734; PMCID: PMC5570678.
      View in: PubMed   Mentions:
    72. Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis. PET Clin. 2017 Jul; 12(3):269-288. Henry KE, Ulaner GA, Lewis JS. PMID: 28576166; PMCID: PMC5545121.
      View in: PubMed   Mentions:
    73. Pathologically Benign Lymph Nodes Can Mimic Malignancy on Imaging in Patients With Angiomatoid Fibrous Histiocytoma. Clin Orthop Relat Res. 2017 Sep; 475(9):2274-2279. Ulaner GA, Healey JH, Athanasian EA. PMID: 28536856; PMCID: PMC5539032.
      View in: PubMed   Mentions:
    74. Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2017 Aug; 44(9):1428-1437. Riedl CC, Pinker K, Ulaner GA, Ong LT, Baltzer P, Jochelson MS, McArthur HL, Gönen M, Dickler M, Weber WA. PMID: 28462446; PMCID: PMC5526620.
      View in: PubMed   Mentions:
    75. Transient Osteoporosis of the Hip on FDG PET/CT. Clin Nucl Med. 2017 May; 42(5):401-402. Ulaner GA, Sawan P. PMID: 28240672; PMCID: PMC5380528.
      View in: PubMed   Mentions:
    76. 18F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer. Eur J Nucl Med Mol Imaging. 2017 Aug; 44(9):1420-1427. Ulaner GA, Castillo R, Wills J, Gönen M, Goldman DA. PMID: 28456837.
      View in: PubMed   Mentions:
    77. Value of second-opinion review of outside institution PET-CT examinations. Nucl Med Commun. 2017 Apr; 38(4):306-311. Ulaner GA, Mannelli L, Dunphy M. PMID: 28291158; PMCID: PMC5354085.
      View in: PubMed   Mentions:
    78. FDG PET/CT Assesses the Risk of Femoral Pathological Fractures in Patients With Metastatic Breast Cancer. Clin Nucl Med. 2017 Apr; 42(4):264-270. Ulaner GA, Zindman AM, Zheng J, Kim TW, Healey JH. PMID: 28166159; PMCID: PMC5334437.
      View in: PubMed   Mentions:
    79. "Comment on Hatzoglou et al.: Dynamic contrast-enhanced MRI perfusion vs 18FDG PET/CT in differentiating brain tumor progression from radiation injury"-Reply. Neuro Oncol. 2017 02 01; 19(2):301-302. Young RJ, Yang TJ, Hatzoglou V, Ulaner G, Omuro A. PMID: 28040711; PMCID: PMC5464186.
      View in: PubMed   Mentions:
    80. 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clin Cancer Res. 2017 Jun 15; 23(12):3053-3060. Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA. PMID: 28011460; PMCID: PMC5474190.
      View in: PubMed   Mentions:
    81. FDG-Avid Intrathecal Inflammation Following Administration of Intrathecal Methotrexate. Clin Nucl Med. 2016 Dec; 41(12):995-997. Hogan MP, Osborne J, Ulaner GA. PMID: 27805919; PMCID: PMC5583704.
      View in: PubMed   Mentions:
    82. Prospective Clinical Trial of 18F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers. J Nucl Med. 2017 07; 58(7):1037-1042. Ulaner GA, Goldman DA, Corben A, Lyashchenko SK, Gönen M, Lewis JS, Dickler M. PMID: 27856630; PMCID: PMC6944156.
      View in: PubMed   Mentions:
    83. Unilateral Suppression of Brown Fat on FDG PET/CT in Horner Syndrome. Clin Nucl Med. 2016 Oct; 41(10):797-8. Ulaner GA, Samstein R, Cahlon O, Weber WA, Rimner A. PMID: 27454597.
      View in: PubMed   Mentions:
    84. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. J Nucl Med. 2016 Oct; 57(10):1523-1528. Ulaner GA, Hyman DM, Ross DS, Corben A, Chandarlapaty S, Goldfarb S, McArthur H, Erinjeri JP, Solomon SB, Kolb H, Lyashchenko SK, Lewis JS, Carrasquillo JA. PMID: 27151988; PMCID: PMC5050126.
      View in: PubMed   Mentions:
    85. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2016 Oct; 43(11):1937-44. Ulaner GA, Castillo R, Goldman DA, Wills J, Riedl CC, Pinker-Domenig K, Jochelson MS, Gönen M. PMID: 27129866; PMCID: PMC5480318.
      View in: PubMed   Mentions:
    86. Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. Am J Nucl Med Mol Imaging. 2016; 6(2):120-7. Marinelli B, Espinet-Col C, Ulaner GA, McArthur HL, Gonen M, Jochelson M, Weber WA. PMID: 27186439; PMCID: PMC4858608.
      View in: PubMed   Mentions:
    87. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0. Eur J Radiol. 2016 Jun; 85(6):1224-31. Shady W, Kishore S, Gavane S, Do RK, Osborne JR, Ulaner GA, Gonen M, Ziv E, Boas FE, Sofocleous CT. PMID: 27161074; PMCID: PMC5675072.
      View in: PubMed   Mentions:
    88. The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by 18F-FDG PET/CT Using PERCIST. J Nucl Med. 2016 07; 57(7):1102-4. Pinker K, Riedl CC, Ong L, Jochelson M, Ulaner GA, McArthur H, Dickler M, Gönen M, Weber WA. PMID: 26985059; PMCID: PMC5493391.
      View in: PubMed   Mentions:
    89. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers. J Nucl Med. 2016 Sep; 57(9):1350-6. Ulaner GA, Goldman DA, Gönen M, Pham H, Castillo R, Lyashchenko SK, Lewis JS, Dang C. PMID: 26940766.
      View in: PubMed   Mentions:
    90. Molecular Imaging of Biomarkers in Breast Cancer. J Nucl Med. 2016 Feb; 57 Suppl 1:53S-9S. Ulaner GA, Riedl CC, Dickler MN, Jhaveri K, Pandit-Taskar N, Weber W. PMID: 26834103; PMCID: PMC4979972.
      View in: PubMed   Mentions:
    91. A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. Neuro Oncol. 2016 06; 18(6):873-80. Hatzoglou V, Yang TJ, Omuro A, Gavrilovic I, Ulaner G, Rubel J, Schneider T, Woo KM, Zhang Z, Peck KK, Beal K, Young RJ. PMID: 26688076; PMCID: PMC4864262.
      View in: PubMed   Mentions:
    92. Detection of Internal Mammary Adenopathy in Patients With Breast Cancer by PET/CT and MRI. AJR Am J Roentgenol. 2015 Oct; 205(4):899-904. Jochelson MS, Lebron L, Jacobs SS, Zheng J, Moskowitz CS, Powell SN, Sacchini V, Ulaner GA, Morris EA, Dershaw DD. PMID: 26397342; PMCID: PMC4970424.
      View in: PubMed   Mentions:
    93. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma. J Nucl Med. 2015 Nov; 56(11):1674-80. Hogan MP, Goldman DA, Dashevsky B, Riedl CC, Gönen M, Osborne JR, Jochelson M, Hudis C, Morrow M, Ulaner GA. PMID: 26294295; PMCID: PMC4869690.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    94. Predictive Value of Positron Emission Tomography/Computed Tomography to Assess Early Treatment Response to Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade Without Chemotherapy for HER2-Positive Metastatic Breast Cancer: Are We Ready to Embrace This "Early Metabolic Look" Strategy? J Clin Oncol. 2015 Aug 20; 33(24):2591-3. Jhaveri K, Ulaner GA, Dickler MN. PMID: 26195716.
      View in: PubMed   Mentions:
    95. Reply: Breast Cancer Staging: To Which Women Should 18F-FDG PET/CT Be Offered? J Nucl Med. 2015 Aug; 56(8):1293-4. Ulaner GA, Riedl CC. PMID: 26112021.
      View in: PubMed   Mentions:
    96. Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma. Radiology. 2015 Nov; 277(2):518-26. Ulaner GA, Goldman DA, Sauter CS, Migliacci J, Lilienstein J, Gönen M, Schöder H, Moskowitz CH, Zelenetz AD. PMID: 26035588; PMCID: PMC5006668.
      View in: PubMed   Mentions:
    97. Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype. Eur J Nucl Med Mol Imaging. 2015 Oct; 42(11):1666-1673. Dashevsky BZ, Goldman DA, Parsons M, Gönen M, Corben AD, Jochelson MS, Hudis CA, Morrow M, Ulaner GA. PMID: 25971426; PMCID: PMC4558334.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    98. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood. 2015 Apr 16; 125(16):2579-81. Sauter CS, Matasar MJ, Meikle J, Schoder H, Ulaner GA, Migliacci JC, Hilden P, Devlin SM, Zelenetz AD, Moskowitz CH. PMID: 25758829; PMCID: PMC4624450.
      View in: PubMed   Mentions:
    99. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. J Nucl Med. 2014 Oct; 55(10):1578-83. Riedl CC, Slobod E, Jochelson M, Morrow M, Goldman DA, Gonen M, Weber WA, Ulaner GA. PMID: 25214641; PMCID: PMC4414239.
      View in: PubMed   Mentions:
    100. Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18F-FDG PET/CT is performed? AJR Am J Roentgenol. 2014 Apr; 202(4):859-67. Ulaner GA, Magnan H, Healey JH, Weber WA, Meyers PA. PMID: 24660717.
      View in: PubMed   Mentions:
    101. FDG PET/CT findings in a rare case of giant fibrovascular polyp of the esophagus harboring atypical lipomatous tumor/well-differentiated liposarcoma. Clin Nucl Med. 2014 Mar; 39(3):288-91. Beylergil V, Simmons MZ, Ulaner G, Jurcic J, Hibshoosh H, Carrasquillo JA. PMID: 24458178.
      View in: PubMed   Mentions:
    102. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma. J Clin Oncol. 2014 Jan 01; 32(1):51-6. Ulaner GA, Lilienstein J, Gönen M, Maragulia J, Moskowitz CH, Zelenetz AD. PMID: 24248697.
      View in: PubMed   Mentions:
    103. FDG-avid venous malformation could mimic malignancy on 18F-FDG PET/CT. Clin Nucl Med. 2013 Oct; 38(10):826-8. Mojtahedi A, Grewal RK, Ulaner GA. PMID: 24107816.
      View in: PubMed   Mentions:
    104. Identifying and distinguishing treatment effects and complications from malignancy at FDG PET/CT. Radiographics. 2013 Oct; 33(6):1817-34. Ulaner GA, Lyall A. PMID: 24108564.
      View in: PubMed   Mentions:
    105. Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. Cancer Med. 2013 Oct; 2(5):725-33. Ulaner GA, Eaton A, Morris PG, Lilienstein J, Jhaveri K, Patil S, Fazio M, Larson S, Hudis CA, Jochelson MS. PMID: 24403238; PMCID: PMC3892804.
      View in: PubMed   Mentions:
    106. Breast implant foreign body reaction mimicking breast cancer recurrence on FDG PET/CT. Clin Nucl Med. 2013 Jun; 38(6):480-1. Ulaner GA, D'Andrea G, Cody HS. PMID: 23640240.
      View in: PubMed   Mentions:
    107. Focused regional FDG PET/CT detects more osseous metastases than does whole-body PET/CT. Clin Nucl Med. 2013 Mar; 38(3):217-8. Mojtahedi A, Solomon SB, Ulaner GA. PMID: 23357824.
      View in: PubMed   Mentions:
    108. Musculoskeletal tumors and tumor-like conditions: common and avoidable pitfalls at imaging in patients with known or suspected cancer: Part A: benign conditions that may mimic malignancy. Int Orthop. 2013 May; 37(5):871-6. Ulaner G, Hwang S, Lefkowitz RA, Landa J, Panicek DM. PMID: 23436133; PMCID: PMC3631500.
      View in: PubMed   Mentions:
    109. Musculoskeletal tumours and tumour-like conditions: common and avoidable pitfalls at imaging in patients with known or suspected cancer: Part B: malignant mimics of benign tumours. Int Orthop. 2013 May; 37(5):877-82. Ulaner G, Hwang S, Landa J, Lefkowitz RA, Panicek DM. PMID: 23417556; PMCID: PMC3631480.
      View in: PubMed   Mentions:
    110. Hill-Sachs lesion on FDG PET/CT. Clin Nucl Med. 2013 Jan; 38(1):65-6. Ulaner GA, Tewari S. PMID: 23242054.
      View in: PubMed   Mentions:
    111. Comparison of the effectiveness of MRI perfusion and fluorine-18 FDG PET-CT for differentiating radiation injury from viable brain tumor: a preliminary retrospective analysis with pathologic correlation in all patients. Clin Imaging. 2013 May-Jun; 37(3):451-7. Hatzoglou V, Ulaner GA, Zhang Z, Beal K, Holodny AI, Young RJ. PMID: 23068052; PMCID: PMC3789370.
      View in: PubMed   Mentions:
    112. False-positive FDG PET/CT due to liver parenchymal injury caused by a surgical retractor. Clin Nucl Med. 2012 Sep; 37(9):910-1. Lyall A, Ulaner GA. PMID: 22889789.
      View in: PubMed   Mentions:
    113. Ipilimumab-induced colitis on FDG PET/CT. Clin Nucl Med. 2012 Jun; 37(6):629-30. Lyall A, Vargas HA, Carvajal RD, Ulaner G. PMID: 22614208.
      View in: PubMed   Mentions:
    114. Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. Cancer. 2012 Nov 15; 118(22):5454-62. Morris PG, Ulaner GA, Eaton A, Fazio M, Jhaveri K, Patil S, Evangelista L, Park JY, Serna-Tamayo C, Howard J, Larson S, Hudis CA, McArthur HL, Jochelson MS. PMID: 22517371.
      View in: PubMed   Mentions:
    115. FDG PET/CT demonstration of right atrium metastasis overlooked on contrast-enhanced CT. Clin Nucl Med. 2011 May; 36(5):405-6. Lu Y, Ulaner G. PMID: 21467869.
      View in: PubMed   Mentions:
    116. B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience. Radiology. 2008 Mar; 246(3):895-902. Ulaner GA, Colletti PM, Conti PS. PMID: 18258810.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    117. An unsuspected MR projectile: a "wooden" chair with metal bracing. J Magn Reson Imaging. 2006 May; 23(5):781-2. Ulaner GA, Colletti PM. PMID: 16568433.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    118. Visualization of telomerase reverse transcriptase (hTERT) promoter activity using a trimodality fusion reporter construct. J Nucl Med. 2006 Feb; 47(2):270-7. Padmanabhan P, Otero J, Ray P, Paulmurugan R, Hoffman AR, Gambhir SS, Biswal S, Ulaner GA. PMID: 16455633; PMCID: PMC4141555.
      View in: PubMed   Mentions:
    119. IVF results in de novo DNA methylation and histone methylation at an Igf2-H19 imprinting epigenetic switch. Mol Hum Reprod. 2005 Sep; 11(9):631-40. Li T, Vu TH, Ulaner GA, Littman E, Ling JQ, Chen HL, Hu JF, Behr B, Giudice L, Hoffman AR. PMID: 16219628.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimalsCells
    120. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer. 2004 Oct; 41(2):155-62. Ulaner GA, Hoffman AR, Otero J, Huang HY, Zhao Z, Mazumdar M, Gorlick R, Meyers P, Healey JH, Ladanyi M. PMID: 15287028.
      View in: PubMed   Mentions:
    121. Telomere maintenance in clinical medicine. Am J Med. 2004 Aug 15; 117(4):262-9. Ulaner GA. PMID: 15308436.
      View in: PubMed   Mentions:
    122. Epigenetic regulation of the taxol resistance-associated gene TRAG-3 in human tumors. Cancer Genet Cytogenet. 2004 May; 151(1):1-13. Yao X, Hu JF, Li T, Yang Y, Sun Z, Ulaner GA, Vu TH, Hoffman AR. PMID: 15120907.
      View in: PubMed   Mentions:
    123. Activating and silencing histone modifications form independent allelic switch regions in the imprinted Gnas gene. Hum Mol Genet. 2004 Apr 01; 13(7):741-50. Li T, Vu TH, Ulaner GA, Yang Y, Hu JF, Hoffman AR. PMID: 14962976.
      View in: PubMed   Mentions:
    124. Epigenetic regulation of Igf2/H19 imprinting at CTCF insulator binding sites. J Cell Biochem. 2003 Dec 01; 90(5):1038-55. Yang Y, Hu JF, Ulaner GA, Li T, Yao X, Vu TH, Hoffman AR. PMID: 14624463.
      View in: PubMed   Mentions:
    125. The histone code regulating expression of the imprinted mouse Igf2r gene. Endocrinology. 2003 Dec; 144(12):5658-70. Yang Y, Li T, Vu TH, Ulaner GA, Hu JF, Hoffman AR. PMID: 12975326.
      View in: PubMed   Mentions:
    126. CTCF binding at the insulin-like growth factor-II (IGF2)/H19 imprinting control region is insufficient to regulate IGF2/H19 expression in human tissues. Endocrinology. 2003 Oct; 144(10):4420-6. Ulaner GA, Yang Y, Hu JF, Li T, Vu TH, Hoffman AR. PMID: 12960026.
      View in: PubMed   Mentions:
    127. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res. 2003 Apr 15; 63(8):1759-63. Ulaner GA, Huang HY, Otero J, Zhao Z, Ben-Porat L, Satagopan JM, Gorlick R, Meyers P, Healey JH, Huvos AG, Hoffman AR, Ladanyi M. PMID: 12702558.
      View in: PubMed   Mentions:
    128. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet. 2003 Mar 01; 12(5):535-49. Ulaner GA, Vu TH, Li T, Hu JF, Yao XM, Yang Y, Gorlick R, Meyers P, Healey J, Ladanyi M, Hoffman AR. PMID: 12588801.
      View in: PubMed   Mentions:
    129. Tissue-specific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development. Int J Cancer. 2001 Mar 01; 91(5):644-9. Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR. PMID: 11267974.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    130. Allelic expression of the putative tumor suppressor gene p73 in human fetal tissues and tumor specimens. Biochim Biophys Acta. 2000 Apr 25; 1491(1-3):49-56. Hu JF, Ulaner GA, Oruganti H, Ivaturi RD, Balagura KA, Pham J, Vu TH, Hoffman AR. PMID: 10760569.
      View in: PubMed   Mentions:
    131. Regulation of telomerase by alternate splicing of human telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium. Int J Cancer. 2000 Feb 01; 85(3):330-5. Ulaner GA, Hu JF, Vu TH, Oruganti H, Giudice LC, Hoffman AR. PMID: 10652422.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    132. Desensitization and resensitization of lutropin receptors expressed in transfected Y-1 adrenal cells. J Endocrinol. 1999 Nov; 163(2):289-97. Ulaner GA, Chuang J, Lin W, Woodbury D, Myers RV, Moyle WR. PMID: 10556779.
      View in: PubMed   Mentions:
    133. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res. 1998 Sep 15; 58(18):4168-72. Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR. PMID: 9751630.
      View in: PubMed   Mentions: 131     Fields:    Translation:HumansCells
    134. Developmental regulation of telomerase activity in human fetal tissues during gestation. Mol Hum Reprod. 1997 Sep; 3(9):769-73. Ulaner GA, Giudice LC. PMID: 9358002.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells